Home    | About Us    | News & Events    | Academic Affiliates    | Contact Us    | Directions

Health Information Services Physicians Referring Physicians Hospitals and Clinics MyHealth Patients & Visitors Faculty & Staff

Ellis Fischel Cancer Center 115 Business Loop 70 W. Columbia, MO 65203 (573) 882-2100 About Clinical Trials Directions Disease Sites Ellis Fischel Gala Ellis Magazine E-mail a Patient E-mail Us Employment Gift Shop Guest House Index A to Z Make a Gift Margaret Proctor Mulligan     Breast Health Center Phone Numbers Physician Information Support Groups Treatment Programs Submit Comments

Mark Hannink, PhD

Professor of Biochemistry

Education:

PhD - University of California, San Diego

Postdoctoral Training - Laboratory of Dr. Howard Temin, McArdle Laboratory for Cancer Research, University of Wisconsin

Research Interests:

Oxidative stress and control of cellular redox homeostasis; regulation of protein ubiquitination; development of novel chemopreventive agents.

Selected Publications:

Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi N, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P and Crowley J: Results of High Dose Therapy for 1,000 Patients with Multiple Myeloma: Durable Complete Remissions and Superior Survival in the Absence of Chromosome 13 Abnormalities. Blood 95:4008-4010, 2000.

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98(2):492-494, 2001.

Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cyotogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Hem 2003; 120:44-52.

Shaughnessy J, Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Jacobson J, Crowley J, Tricot G. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with Toal Therapy I; interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.

Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood 2004; 103:20-32.